Bioatla

Bioatla R&D / Revenue

The R&D to Revenue Ratio of Bioatla (BCAB) as of Nov 18, 2026 is 2,178.65 %. In the previous year, R&D to Revenue Ratio was 573.59 % — a change of 279.83% (higher).

R&D / Revenue

2,178.65 %

YoY

279.83%

Last updated:

R&D to Revenue Ratio of Bioatla is 2025 2,178.65 % . R&D to Revenue Ratio of Bioatla was 2024 573.59 % . It decreases by 279.83% higher compared to the previous year.

The Bioatla R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2018
247.53 USD
Jan 1, 2019
498.44 USD
Jan 1, 2020
4,646.39 USD
Jan 1, 2021
23,309.60 USD
Jan 1, 2024
573.59 USD
Jan 1, 2025
2,178.65 USD
The Bioatla R&D / Revenue history
YEARR&D / RevenueYoY
2,178.65 %+279.83%
573.59 %-97.54%
23,309.60 %+401.67%
4,646.39 %+832.18%
498.44 %+101.37%
247.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioatla stock

R&D to Revenue Ratio of Bioatla is 2,178.65 % in 2025.

R&D to Revenue Ratio of Bioatla changed from 573.59 % to 2,178.65 %, representing a 279.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Bioatla since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Bioatla with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bioatla

All Key Metrics — Bioatla